Metacrine’s FXR Program to be Highlighted in Three Abstracts at The Liver Meeting® 2017 in Washington, D.C.

October 10, 2017

San Diego, CA - Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it will present three abstracts on its novel FXR agonist program at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Washington, D.C. ... READ MORE

Metacrine Announces Collaboration on Development of FGF1 Variants for Glucose Lowering and Improving Insulin Sensitivity

August 15, 2017

San Diego, CA - Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it has entered a collaboration with Novo Nordisk A/S to develop Fibroblast Growth Factor 1 (“FGF1”) variants for glucose lowering and insulin sensitization. ... READ MORE

Metacrine to Present Two Abstracts on its Novel FXR Non-Bile Acid Agonist Program at the EASL International Liver Congress 2017

April 11, 2017

San Diego, CA - Metacrine, Inc., a leading and innovative biotechnology company focused on drug development for metabolic diseases, announced it will present two abstracts on its novel FXR agonist program at the upcoming International Liver Congress Meeting of the European Association for the Study of Liver Disease (EASL) in Amsterdam, Netherlands. Metacrine has developed a leading and comprehensive FXR agonist program based on a unique non-bile acid chemical scaffold ... READ MORE

Metacrine Expands Patent Portfolio for Novel FGF-1 Program to Treat Diabetes

October 17, 2016

San Diego, CA - Metacrine, Inc., a leading biotechnology company efficiently developing innovative drugs for metabolic diseases, announced the issuance of a new patent by the U.S. Patent and Trademark Office that supports development for the company’s FGF-1 program ... READ MORE

Metacrine Announces Appointment of Dr. Ken Song as President and Chief Executive Officer

September 14, 2016

San Diego, CA - Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, today announced the appointment of Ken Song, M.D., as its new president, chief executive officer and director ... READ MORE

Metacrine Raises $36 Million in Series A Financing

August 5, 2015

San Diego, CA - Metacrine, Inc., a biotechnology company focused on targeting metabolic disease through advances in endocrine research, today announced it has raised $36 million in a Series A financing... READ MORE